-
The insulin giant's stock price has been falling all the way!
Time of Update: 2022-05-07
Among them, Insulin Glargine Injection (Chang Xiulin) is the flagship product of Gan & Lee Pharmaceuticals, whose sales revenue accounts for more than 90% of the total revenue every year, and the product structure is single .
-
After the results of the medical insurance negotiation were released, how did the market react?
Time of Update: 2022-05-07
For example, Hengrui Medicine has a total of 7 products included in the medical insurance this time, including Fluzoparib Capsules, Hetrombopag Ethanolamine Tablets, 3 innovative drugs of Remazolam Tosylate for Injection, and the first domestic imitation antihypertensive drug A.
-
Changes in the pharmaceutical sector, two traditional Chinese medicine stocks daily limit
Time of Update: 2022-05-07
According to the analysis, there are two reasons for the change of the stock: First, the company is a pharmaceutical company engaged in the research and development, production and sales of modern traditional Chinese medicine and characteristic chemical generic drugs .
-
The traditional Chinese medicine sector rose sharply, and many individual stocks rose by the daily limit
Time of Update: 2022-05-07
From the above overall point of view, many traditional Chinese medicine companies are expected to usher in double highs in performance and stock price in the next few years under the continuous development of the industry .
-
On December 6, Xinhua Pharmaceuticals hit the daily limit, and it has increased the daily limit 4 times during the year
Time of Update: 2022-05-07
[Pharmaceutical Network Pharmaceutical Stock Market] According to news on December 6, Xinhua Pharmaceutical hit the daily limit at the opening.
-
The popularity of the traditional Chinese medicine sector continues, and this new stock will be listed in Hong Kong
Time of Update: 2022-05-07
Recently, the news that a Chinese medicine medical and health service provider, Gushengtang, is about to be listed on the main board of the Hong Kong Stock Exchange has attracted widespread attention in the industry and attracted a number of large institutions.
-
The pharmaceutical manufacturing sector fell by 2% today, and five pharmaceutical companies fell by more than 7%
Time of Update: 2022-05-05
According to the 2020 annual report, Lai Mei Pharmaceutical is already developing a drug for intermediate and advanced liver cirrhosis-individualized anti-hepatic fibrosis macrophage injection.
-
Dental projects are expected to be included in commercial insurance, and Modern Dental and Times Angel rose by more than 8%
Time of Update: 2022-05-04
Industry analysis pointed out that the reason why dental treatment is expensive is mainly due to the high cost of materials and labor, and related to most items of oral treatment that are not covered by medical insurance, such as simple filling surgery, complex filling surgery, root canal treatment and other dental treatments.
-
The trend of the medical sector is differentiated, and the concept of Internet medical care and CRO is showing strong performance
Time of Update: 2022-05-04
For example, in May this year, the "Guiding Opinions on Establishing and Improving the "Dual-Channel" Management Mechanism for Drugs Negotiated by National Medical Insurance" issued by the two departments stipulates that varieties with high clinical value, urgent needs of patients, and low substitution should be included in designated medical institutions in a timely manner.
-
The medical device sector picks up, and Kanglongda hits the daily limit
Time of Update: 2022-05-04
According to news on September 27, Kanglongda hit the daily limit, and many medical device concept stocks such as Opcon Vision followed suit .
-
The pharmaceutical sector index remains stable as a whole, and these pharmaceutical companies are recommended by a stable combination this week
Time of Update: 2022-05-04
537 billion yuan; net profit attributable to shareholders of listed companies increased by 55.
Analysts said that as a large company in the industry, it can still have such growth in performance, which proves the competitiveness of its business model .
-
The pharmaceutical sector ushered in a rebound, and Zhifei Bio rose nearly 15%
Time of Update: 2022-05-04
Looking forward to the future, I am optimistic about diversified investment opportunities in pharmaceutical stocks, such as CXO, medical devices, innovative drug tracks, as well as vaccines and pharmacies.
-
The medical device sector is trending strongly, with Weigao Orthopedics and Chunli Medical up more than 4%
Time of Update: 2022-05-04
In the news, in addition to the proposed selection results of artificial joints, MicroPort Medical recently also issued an announcement that Shanghai MicroPort as a strategic investor will acquire 45% of Fujian Kerui Pharmaceutical held by the transferor for about 111 million yuan.
-
Hong Kong stock pharmaceutical stocks broke out, and many individual stocks rose by more than 10%
Time of Update: 2022-05-04
GenScript Biotechnology recently announced that its biopharmaceutical contract R&D and production organization (CDMO) GenScript Biopharmaceuticals and Hefei Tiangang Immunopharmaceuticals have reached a new antibody drug project cooperation .
-
The stock price and market value have doubled within two months, and this pharmaceutical company has been investigated by institutions.
Time of Update: 2022-05-04
In addition, for the doubling of the stock price, Fuxiang Pharmaceutical explained that there are three main reasons for the continuous rise of the company's stock price since the end of July: First, it established a joint venture with Lingkai Pharmaceutical to establish Shanghai Lingfu Research Co.
-
There was a change in the pharmaceutical sector of Hong Kong stocks, and individual stocks such as WuXi AppTec and BeiGene rose significantly
Time of Update: 2022-05-04
Ping An Securities released a research report saying that the core products of Corning & Jereh Pharmaceuticals are progressing smoothly, and this year is expected to start the first year of commercialization .
-
This new pharmaceutical stock has officially landed on the GEM!
Time of Update: 2022-05-04
00% of the shares of Tibet Jiakang; at the same time, Deng Yong is the executive partner of Tibet Qingchang, and indirectly controls 9.
63% of the shares of Tibet Dorui in total and is the actual controller of the company .
-
The CXO sector continues to be booming, with more than 90% of stocks rising by more than 10%
Time of Update: 2022-05-04
It is reported that this time Jiuzhou Pharmaceutical intends to increase the capital of Siwei Pharmaceutical by 30 million yuan, the main body of the “Zhejiang Siwei Pharmaceutical Technology Co.
-
The biopharmaceutical sector of Hong Kong stocks continues to strengthen, and a pharmaceutical company rises more than 20%
Time of Update: 2022-05-04
It is reported that WuXi Junuo announced last Friday that the CAR-T therapy product "Ruijirenxai Injection" (JWCAR029) has been approved for marketing for adult patients with relapsed or refractory severe disease after second-line or above systemic therapy.
-
Industry: Chinese medicine stocks are expected to usher in rising opportunities
Time of Update: 2022-05-04
Judging from the performance of major traditional Chinese medicine companies in the first half of the year, more than 70% of their revenue and net profit rose.
The company achieved a net profit of 520 million attributable to the parent in the first half of 2021, a year-on-year increase of 1865.
